Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **fatty acid degradation pathway** (also called fatty acid β-oxidation or fatty acid oxidation, FAO) is a highly conserved metabolic process whereby fatty acids—after activation by conversion to acyl-CoA—are transported into mitochondria or peroxisomes and sequentially degraded through cycles of oxidation, hydration, and cleavage to produce acetyl-CoA, NADH, and FADH₂, which feed into the TCA cycle and the electron transport chain to generate ATP[1][2][3][4][5][8]. Major steps include lipolysis, fatty acid activation, mitochondrial or peroxisomal import, and β-oxidation cycles[1][3][5][8]. Dysregulation of the pathway or inherited enzyme deficiencies can cause energy metabolism disorders and contribute to pathologies including cancer, heart disease, and immunological dysfunction[2][4].
Not applicable at the pathway level. For enzyme inhibitors, e.g., CPT1 inhibition reduces β-oxidation and lowers ATP production from fatty acid catabolism[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fatty acid degradation pathway.